How complete is "complete" molecular response in imatinib-treated chronic myeloid leukemia?

Leukemia and Lymphoma

Volumn 49, Issue 7, 2008, Pages 1230-1231

  Ross, David M ^a   Hughes, Timothy P ^a  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ALPHA INTERFERON; BCR ABL PROTEIN; IMATINIB; MESSENGER RNA;

ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME INHIBITION; HUMAN; NOTE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THERAPY EFFECT; TREATMENT DURATION;

HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM, RESIDUAL; PIPERAZINES; PYRIMIDINES; RECURRENCE; REMISSION INDUCTION;

EID: 47649127151     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802158461     Document Type: Note

References (7)

1. Verma, D., Kantarjian, H., Jain, N. and Cortes, J. (2008) Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukaemia not previously exposed to interferon alpha. Leuk Lymph, 49, pp. 1399-1402.
2. Branford, S., Seymour, J. F., Grigg, A., Arthur, C., Rudzki, Z. Lynch, K. et al. (2007) BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res, 13, pp. 7080-7085.
3. Lange, T., Bumm, T., Mueller, M., Otto, S., Al-Ali, H. K. Grommisch, L. et al. (2005) Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation. Leukemia, 19, pp. 1262-1265.
4. Michor, F., Hughes, T. P., Iwasa, Y., Branford, S., Shah, N. P. Sawyers, C. L. et al. (2005) Dynamics of chronic myeloid leukaemia. Nature, 435, pp. 1267-1270.
5. Roeder, I., Horn, M., Glauche, I., Hochhaus, A., Mueller, M. C. and Loeffler, M. (2006) Dynamic modeling of imatinib-treated chronic myeloid leukemia: Functional insights and clinical implications. Nat Med, 12, pp. 1181-1184.
6. Holyoake, T., Jiang, X., Eaves, C. and Eaves, A. (1999) Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood, 94, pp. 2056-2064.
7. Rousselot, P., Huguet, F., Rea, D., Legros, L., Cayuela, J. M. Maarek, O. et al. (2007) Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood, 109, pp. 58-60.